<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01070966</url>
  </required_header>
  <id_info>
    <org_study_id>0653A-174</org_study_id>
    <secondary_id>2010_010</secondary_id>
    <nct_id>NCT01070966</nct_id>
  </id_info>
  <brief_title>Vytorin Reexamination Study (0653A-174)</brief_title>
  <official_title>Re-examination Study for General Drug Use to Assess the Safety and Efficacy Profile of VYTORIN in Usual Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This survey is conducted for preparing application material for re-examination under the
      Pharmaceutical Affairs Laws and its Enforcement Regulation, its aim is to reconfirm the
      clinical usefulness of VYTORIN through collecting the safety and efficacy information
      according to the Re-examination Regulation for New Drugs.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Any Clinical and/or Laboratory Adverse Experiences While Taking VYTORIN® Within 14 Days After Treatment Discontinuation</measure>
    <time_frame>Up to 14 days after the treatment discontinuation</time_frame>
    <description>Participants who recieved VYTORIN and experienced any adverse event related or unrelated to VYTORIN®, within 14 days after treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Percent Change From Baseline to Treatment in Lipid Parameters</measure>
    <time_frame>Baseline and up to 5 years</time_frame>
    <description>The mean percent change from baseline to treatment in lipid parameters (total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides[TG]) and overall efficacy was evaluated by the investigator to show if there was any(improved, unchanged, worsened) lipid parameters over a period of approximately 5 years.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">2089</enrollment>
  <condition>Primary Hypercholesterolemia and Homozygous Familial Hypercholesterolemia (HoFH)</condition>
  <arm_group>
    <arm_group_label>VYTORIN® 10/10 (ezetimibe 10 mg/simvastatin 10 mg tablets)</arm_group_label>
    <description>Participants with Hypercholesterolemia and Homozygous Familial Hypercholesterolemia (HoFH) treated with VYTORIN® 10/10 (ezetimibe 10 mg/simvastatin 10 mg tablets)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VYTORIN® 10/20 (ezetimibe 10 mg/simvastatin 20 mg tablets)</arm_group_label>
    <description>Participants with Hypercholesterolemia and Homozygous Familial Hypercholesterolemia (HoFH) treated with VYTORIN® 10/20 (ezetimibe 10 mg/simvastatin 20 mg tablets)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VYTORIN® 10/40 (ezetimibe 10 mg/simvastatin 40 mg tablets)</arm_group_label>
    <description>Participants with Hypercholesterolemia and Homozygous Familial Hypercholesterolemia (HoFH) treated with VYTORIN® 10/40 (ezetimibe 10 mg/simvastatin 40 mg tablets)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VYTORIN® 10/80 (ezetimibe 10 mg/simvastatin 80 mg tablets)</arm_group_label>
    <description>Participants with Hypercholesterolemia and Homozygous Familial Hypercholesterolemia (HoFH) treated with VYTORIN® 10/80 (ezetimibe 10 mg/simvastatin 80 mg tablets)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with Primary Hypercholesterolemia and Homozygous Familial Hypercholesterolemia
        (HoFH) treated with Vytorin
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants Who Receives Vytorin In Usual Medical Practice Within Local Label For The
             First Time
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Korea, Republic of</country>
  </removed_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2010</study_first_submitted>
  <study_first_submitted_qc>February 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2010</study_first_posted>
  <results_first_submitted>April 14, 2011</results_first_submitted>
  <results_first_submitted_qc>April 14, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 10, 2011</results_first_posted>
  <last_update_submitted>October 30, 2015</last_update_submitted>
  <last_update_submitted_qc>October 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atherosclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Ezetimibe, Simvastatin Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>VYTORIN® 10/10 mg/Day to 10/80 mg/Day</title>
          <description>Participants with Hypercholesterolemia and Homozygous Familial Hypercholesterolemia (HoFH)treated with VYTORIN® dosages ranging from 10/10(ezetimibe 10 mg/simvastatin 10 mg tablets)a day to 10/80(ezetimibe 10 mg/simvastatin 80 mg tablets)a day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Participants for Safety Evaluation</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2089"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2011"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Violation of inclusion criteria</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Off-label use</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Duplicate Participants</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Violation inclusion criteria/off label</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>TMT given before date of contract</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Participants for Efficacy Evaluation</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2011"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1929"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of tmt period (&lt;28 days)</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No efficacy evaluation</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Efficacy evaluation window violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>VYTORIN® 10/10 mg/Day to 10/80 mg/Day</title>
          <description>Participants with Hypercholesterolemia and Homozygous Familial Hypercholesterolemia (HoFH) treated with VYTORIN® ranging from 10/10 mg/day through 10/80 mg/day for Years 1 to 6.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2011"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>10 ≤age &lt;20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 ≤age &lt;30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 ≤age &lt;40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40 ≤age &lt;50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50 ≤age &lt;60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="598"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 ≤age &lt;70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70 ≤age &lt;80</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80 ≤age &lt;90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="930"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1081"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Any Clinical and/or Laboratory Adverse Experiences While Taking VYTORIN® Within 14 Days After Treatment Discontinuation</title>
        <description>Participants who recieved VYTORIN and experienced any adverse event related or unrelated to VYTORIN®, within 14 days after treatment.</description>
        <time_frame>Up to 14 days after the treatment discontinuation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Participants Treated With VYTORIN</title>
            <description>Participants with atherosclerosis treated with Vytorin ranging from 10/10 mg/day through 10/80 mg/day for Years 1 to 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Any Clinical and/or Laboratory Adverse Experiences While Taking VYTORIN® Within 14 Days After Treatment Discontinuation</title>
          <description>Participants who recieved VYTORIN and experienced any adverse event related or unrelated to VYTORIN®, within 14 days after treatment.</description>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2011"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Percent Change From Baseline to Treatment in Lipid Parameters</title>
        <description>The mean percent change from baseline to treatment in lipid parameters (total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides[TG]) and overall efficacy was evaluated by the investigator to show if there was any(improved, unchanged, worsened) lipid parameters over a period of approximately 5 years.</description>
        <time_frame>Baseline and up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Participants Baseline Lipid Parameters</title>
            <description>Participants baseline lipid parameters for Total Cholesterol, HDL cholesterol, LDL cholesterol and Triglyceride.</description>
          </group>
          <group group_id="O2">
            <title>Participants Treatment Lipid Parameters</title>
            <description>Participants treatment lipid parameters for Total Cholesterol, HDL cholesterol, LDL cholesterol and Triglyceride.</description>
          </group>
          <group group_id="O3">
            <title>Participants Percent Change</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline to Treatment in Lipid Parameters</title>
          <description>The mean percent change from baseline to treatment in lipid parameters (total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides[TG]) and overall efficacy was evaluated by the investigator to show if there was any(improved, unchanged, worsened) lipid parameters over a period of approximately 5 years.</description>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2011"/>
                <count group_id="O2" value="2011"/>
                <count group_id="O3" value="2011"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TC (n = 1965, 1993, 1956)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231.31" spread="46.33"/>
                    <measurement group_id="O2" value="173.00" spread="40.78"/>
                    <measurement group_id="O3" value="-23.90" spread="17.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL (n = 1805, 1782, 1705)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.64" spread="13.42"/>
                    <measurement group_id="O2" value="49.85" spread="13.17"/>
                    <measurement group_id="O3" value="2.06" spread="15.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL (n = 1096, 1128, 1012)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151.32" spread="39.09"/>
                    <measurement group_id="O2" value="104.34" spread="37.09"/>
                    <measurement group_id="O3" value="-28.93" spread="23.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TG (n = 1843, 1824, 1766)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200.07" spread="128.76"/>
                    <measurement group_id="O2" value="168.33" spread="102.82"/>
                    <measurement group_id="O3" value="-7.37" spread="41.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Year 1 through Year 6. There were no SAE's reported in Year three.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>VYTORIN YEAR 1</title>
          <description>Participants with atherosclerosis treated with Vytorin ranging from 10/10 mg/day through 10/80 mg/day for Year 1</description>
        </group>
        <group group_id="E2">
          <title>VYTORIN YEAR 2</title>
          <description>Participants with atherosclerosis treated with Vytorin ranging from 10/10 mg/day through 10/80 mg/day for Year 2</description>
        </group>
        <group group_id="E3">
          <title>VYTORIN YEAR 4</title>
          <description>Participants with atherosclerosis treated with Vytorin ranging from 10/10 mg/day through 10/80 mg/day for Year 4</description>
        </group>
        <group group_id="E4">
          <title>VYTORIN YEAR 5</title>
          <description>Participants with atherosclerosis treated with Vytorin ranging from 10/10 mg/day through 10/80 mg/day for Year 5</description>
        </group>
        <group group_id="E5">
          <title>VYTORIN YEAR 6</title>
          <description>Participants with atherosclerosis treated with Vytorin ranging from 10/10 mg/day through 10/80 mg/day for Year 6</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="933"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="531"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="933"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="933"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VERTIGO POSITIONAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="933"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>DIABETIC RETINOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="933"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GASTRIC ULCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="933"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="933"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>RETROPERITONEAL HAEMATOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="933"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="933"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="933"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS ACUTE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="933"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DIABETIC FOOT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="933"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="933"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>GOUTY ARTHRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="933"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>SPINAL COLUMN STENOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="933"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>CERVIX CARCINOMA RECURRENT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="933"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="933"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="933"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="531"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="933"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="531"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="380"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President, Late Stage Development Group Leader</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

